CA2251281A1 - Drug composition with controlled drug release rate - Google Patents

Drug composition with controlled drug release rate

Info

Publication number
CA2251281A1
CA2251281A1 CA002251281A CA2251281A CA2251281A1 CA 2251281 A1 CA2251281 A1 CA 2251281A1 CA 002251281 A CA002251281 A CA 002251281A CA 2251281 A CA2251281 A CA 2251281A CA 2251281 A1 CA2251281 A1 CA 2251281A1
Authority
CA
Canada
Prior art keywords
drug
release rate
drug composition
controlled
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002251281A
Other languages
French (fr)
Other versions
CA2251281C (en
Inventor
Makoto Suzuki
Kenji Ishigaki
Minoru Okada
Kenji Ono
Shuichi Kasai
Katsumi Imamori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd filed Critical SSP Co Ltd
Publication of CA2251281A1 publication Critical patent/CA2251281A1/en
Application granted granted Critical
Publication of CA2251281C publication Critical patent/CA2251281C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

This invention relates to a drug composition with a controlled drug release rate. The drug composition comprises: a matrix formed of the following ingredients (a) and (b): (a) a biodegradable, biocompatible high-molecular substance and/or polyvalent metal ions or polyvalent metal ion source, and (b) hyaluronic acid or a salt thereof; and a drug incorporated as an ingredient (c) in said matrix. The drug composition has biodegradability and biocompatibility, permits easy control of a release rate of the drug, and can persistently exhibit its pharmacological effect over a long time.
CA002251281A 1997-10-27 1998-10-20 Drug composition with controlled drug release rate Expired - Fee Related CA2251281C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29400897A JP4234803B2 (en) 1997-10-27 1997-10-27 Pharmaceutical composition with controlled drug release rate
JP9-294008 1997-10-27

Publications (2)

Publication Number Publication Date
CA2251281A1 true CA2251281A1 (en) 1999-04-27
CA2251281C CA2251281C (en) 2007-09-11

Family

ID=17802062

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251281A Expired - Fee Related CA2251281C (en) 1997-10-27 1998-10-20 Drug composition with controlled drug release rate

Country Status (10)

Country Link
US (1) US6375988B1 (en)
EP (1) EP0913149B1 (en)
JP (1) JP4234803B2 (en)
KR (1) KR100535319B1 (en)
CN (1) CN1136842C (en)
CA (1) CA2251281C (en)
DE (1) DE69829254T2 (en)
ES (1) ES2239376T3 (en)
HK (1) HK1019142A1 (en)
TW (1) TW520292B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303988B2 (en) 2000-10-13 2012-11-06 Shionogi Inc. Antifungal once-a-day product, use and formulation thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
KR100236771B1 (en) * 1997-04-01 2000-02-01 성재갑 Hyaluronate microparticles for sustained release of drug
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
WO2002100425A1 (en) * 2001-06-11 2002-12-19 Ltt Institute Co., Ltd. Aggregate composition for sustained-release preparation, process for producing the same, and sustained-release preparation containing the same
GB0129489D0 (en) * 2001-12-10 2002-01-30 Quadrant Healthcare Uk Ltd Sustained-release compositions
EP1787643A1 (en) * 2004-09-09 2007-05-23 Jimenez Bayardo, Arturo Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
KR100939983B1 (en) * 2006-10-31 2010-02-03 주식회사 엘지생명과학 Hyaluronic Acid and Hydrophobic Poly Amino Acid Copolymer
JP5255775B2 (en) * 2007-03-15 2013-08-07 ピアス株式会社 Aqueous gel, external preparation for skin and cosmetics
EP2750665A1 (en) 2011-09-02 2014-07-09 Novozymes Biopharma DK A/S Oral formulations containing hyaluronic acid for sustained drug release
SG10201510437WA (en) * 2011-10-03 2016-01-28 Univ Nanyang Tech Cationic peptidopolysaccharides with excellent broad-spectrum antimicrobial activities and high selectivity
ES2518866T3 (en) * 2011-12-23 2014-11-05 Aap Implantate Ag Sterile emulsion containing hyaluronate and glucocorticoid, and use of such emulsion in the treatment of inflammatory joint disorders
JP6120397B2 (en) * 2012-10-11 2017-04-26 ポーラ化成工業株式会社 Method for producing nanoparticles containing chitosan and hyaluronan
CN105517539A (en) 2013-08-21 2016-04-20 Nrl制药股份有限公司 Method for producing microparticles
CN106665645B (en) * 2016-12-22 2019-08-27 德州京信药业有限公司 A kind of refining dipterex composition and the preparation method and application thereof
KR102610937B1 (en) * 2018-10-30 2023-12-08 (주)아모레퍼시픽 Crosslinked hyaluronic acid compositions and method of producing the same
KR102501175B1 (en) * 2020-02-03 2023-02-16 엠앤에이치바이오 주식회사 Controlled release formulations for treating hearing loss and method of preparing the same
KR102597505B1 (en) * 2020-06-01 2023-11-02 주식회사 엘지화학 A method of preparing polymeric micro particles, polymeric micro particles, medical composition, cosmetic composition, medical articles and cosmetic articles using the same
CN114269813B (en) * 2020-06-01 2024-01-02 株式会社Lg化学 Method for preparing polymer microparticles, and medical composition, cosmetic composition, medical article and cosmetic article using the same
KR20230047294A (en) * 2021-09-30 2023-04-07 주식회사 엘지화학 Micro carrier, cell composite, and medical composition, cosmetic composition, medical articles and cosmetic articles using the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
EP0187703B1 (en) * 1985-01-11 1992-08-05 Teijin Limited Sustained release preparation
JPS61253065A (en) * 1985-05-02 1986-11-10 片倉チツカリン株式会社 Medical composite material of chitosan derivative and collagen and its production
JP2837675B2 (en) * 1987-09-22 1998-12-16 中外製薬株式会社 Sustained-release fine-particle preparation
EP0528971B1 (en) * 1990-05-14 1999-09-01 JERNBERG, Gary R. Surgical implant and method incorporating chemotherapeutic agents
JPH04124127A (en) * 1990-09-14 1992-04-24 Chugai Pharmaceut Co Ltd Microcapsule type sustained releasable preparation and its production
IT1243390B (en) * 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
JP3283288B2 (en) * 1991-03-08 2002-05-20 電気化学工業株式会社 Bioactive peptide preparation
JPH04282322A (en) * 1991-03-08 1992-10-07 Denki Kagaku Kogyo Kk Bioactive peptide preparation
JPH0565231A (en) * 1991-03-12 1993-03-19 Takeda Chem Ind Ltd Sustained release pharmaceutical of erythropoietin
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4115454A1 (en) * 1991-05-11 1992-11-12 Basf Ag Iron (III) -HYALURONATE
JP3449738B2 (en) * 1991-07-10 2003-09-22 武田薬品工業株式会社 Water-soluble composition
WO1993008818A1 (en) 1991-11-07 1993-05-13 The University Of Southern California Compositions and methods for preventing adhesion formation
IT1254170B (en) 1991-12-18 1995-09-11 Mini Ricerca Scient Tecnolog COMPOSITE MEMBRANES FOR GUIDED REGENERATION OF FABRICS
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9206509D0 (en) * 1992-03-25 1992-05-06 Jevco Ltd Heteromorphic sponges containing active agents
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
JPH05310580A (en) * 1992-04-30 1993-11-22 Shiseido Co Ltd Liquid preparation for entopic perfusion
JPH06100468A (en) * 1992-09-25 1994-04-12 Kibun Food Chemifa Co Ltd Sustained release composition
US5399358A (en) 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
IT1273742B (en) * 1994-08-01 1997-07-09 Lifegroup Spa HIGH BIO ADHESIVE AND MUCO ADHESIVE COMPOSITIONS USEFUL FOR THE TREATMENT OF EPITALS AND MUCOSES
JPH08198724A (en) * 1995-01-19 1996-08-06 Yakult Honsha Co Ltd Skin cosmetic
JPH09221420A (en) * 1995-12-15 1997-08-26 Takeda Chem Ind Ltd Sustained release agent of hydroxamic acid compound
KR100236771B1 (en) * 1997-04-01 2000-02-01 성재갑 Hyaluronate microparticles for sustained release of drug
US5885609A (en) * 1997-05-23 1999-03-23 Northeastern University Biocompatible articles and method for making same
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303988B2 (en) 2000-10-13 2012-11-06 Shionogi Inc. Antifungal once-a-day product, use and formulation thereof

Also Published As

Publication number Publication date
DE69829254T2 (en) 2005-08-18
ES2239376T3 (en) 2005-09-16
TW520292B (en) 2003-02-11
EP0913149A1 (en) 1999-05-06
JPH11130697A (en) 1999-05-18
CA2251281C (en) 2007-09-11
US6375988B1 (en) 2002-04-23
KR19990037094A (en) 1999-05-25
CN1136842C (en) 2004-02-04
KR100535319B1 (en) 2006-04-21
DE69829254D1 (en) 2005-04-14
EP0913149B1 (en) 2005-03-09
CN1220874A (en) 1999-06-30
HK1019142A1 (en) 2000-01-14
JP4234803B2 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
CA2251281A1 (en) Drug composition with controlled drug release rate
AU582920B2 (en) Continuous release pharmaceutical compositions
DE69128621T2 (en) BIOKERAMIC SYSTEM FOR DELIVERING BIOACTIVE SUBSTANCES
IE882727L (en) Sustained release pharmaceutical compositions
AU2348988A (en) 4H-1-benzopyran-4-one derivative or its salt, processes for producing the same and pharmaceutical composition comprising the same as active ingredient
BR9408072A (en) Vesicles with controlled release of assets
CA2235919A1 (en) Non-polymeric sustained release delivery system
MY107500A (en) Preparation process of sustained release compositions and the compositions thus obtained
CA2107709A1 (en) Calcium Agent for Plants
CA2158638A1 (en) A Composition and a Method for Tissue Augmentation
MY127797A (en) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
EP0573094A3 (en) Absorbable blend for controlled release
CA2147341A1 (en) Skin treatment composition comprising l-lactic acid and n-acetyl-l-cysteine
AU3091489A (en) Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
ATE316779T1 (en) IMPLANTS FOR THE CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS AND METHOD FOR THE PRODUCTION
AU5283890A (en) Fibroblast growth factor (fgf)-based stabilized compositions
CA2163218A1 (en) New macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
CA2325983A1 (en) Drug delivery of proteins from polymeric blends
CA2202676A1 (en) Biodegradable polyanhydrides derived from dimers of bile acids, and use thereof as controlled drug release systems
CA2192481A1 (en) Drug salts
GB9505082D0 (en) Medicament
DE69208171D1 (en) Drugs containing delayed release of active ingredients containing bile acids
HUT66079A (en) Pharmaceutical compositions containing hirudin as active component
AU7308296A (en) Stabilised pharmaceutical compositions containing dobutamine
AU6683090A (en) Biodegradable, water-soluble polycarboxylic acid copolymers, compositions containing such copolymers and methods of use of such copolymers

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161020